SCHEMBL18591925

SCHEMBL18591925

CCCOc1ccc2cc(C(=O)OCC)oc2c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 5/20 0.57
CA7 P43166 5/20 0.57
CA9 Q16790 5/20 0.57
CA2 P00918 4/20 0.57
CA6 P23280 4/20 0.57
CA14 Q9ULX7 4/20 0.57
CA1 P00915 4/20 0.57
CA5B Q9Y2D0 4/20 0.57
CA5A P35218 3/20 0.57
ALDH1A1 P00352 5/20 0.54
KDM4E B2RXH2 4/20 0.54
GLA P06280 4/20 0.54
GAA P10253 4/20 0.54
HPGD P15428 4/20 0.54
MAPT P10636 3/20 0.54
HSD17B10 Q99714 2/20 0.54
MAPK1 P28482 2/20 0.54
TP53 P04637 1/20 0.54
MAOB P27338 7/20 0.54
CA4 P22748 4/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13740830 0.95 CA12 (0.57) CA12CA7CA9CA2CA6
SCHEMBL18591911 0.90 MAOB (0.52) CA12CA7CA9CA2CA6
SCHEMBL177458 0.85 HPGD (0.70) CA12CA7CA9CA2CA6
SCHEMBL18591922 0.85 CA9 (0.61) CA12CA7CA9CA2CA6
SCHEMBL18611964 0.84 MAOB (0.52) CA12CA7CA9CA2CA6
SCHEMBL16418952 0.84 KDM4E (0.77) CA12CA7CA9CA2CA6
SCHEMBL8115506 0.84 SLC2A1 (0.73) CA12CA7CA9CA2CA6
SCHEMBL744596 0.84 MAOB (0.76) CA12CA7CA9CA2CA6
SCHEMBL8223059 0.83 MAOA (0.67) CA12CA7CA9CA2CA6
SCHEMBL3619684 0.83 SLC2A1 (0.56) CA12CA7CA9CA2CA6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230263893-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS ARVINAS OPERATIONS, INC. 2023-08-24 US disclosed
US-20170065719-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS ARVINAS OPERATIONS, INC. 2017-03-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230263893-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS BRPF3, STUB1, BRDT CA12 3495/4885CA7 3959/4885CA9 3703/4885
US-20170065719-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS BRPF3, STUB1, BRDT CA12 3495/4885CA7 3959/4885CA9 3703/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.